← All trials
NCT06978621
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 25, 2025
- Primary completion
- Aug 31, 2025
- Completion date
- Sep 30, 2025
- First posted
- May 18, 2025
- Last posted
- Jun 17, 2025
- Enrollment
- 36
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chiangmai UniversityLead sponsor
- Chiangmai UniversityOfficial
- Chiangmai UniversityCollaborator
- Chiangmai UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.